Biotechnology The US subsidiary of Chinese biotech VelaVigo Cayman Limited has announced its second out-licensing agreement of a first-in-class (FIC) asset, this time to US biotech start-up Ollin Biosciences, granting the latter an exclusive license to develop, manufacture and commercialize VBS-102, a first-in-class bispecific antibody, globally (excluding Greater China). 21 April 2025